Clinical Trials of Intravenous Immunoglobulin for Alzheimer’s Disease

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Intravenous immunoglobulin: Exploiting the potential of natural antibodies

(2012) Srini V. Kaveri   AUTOIMMUNITY REVIEWS

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

(2012) Lakshman Puli et al.   Journal of Neuroinflammation

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

(2011) Sergio T. Ferreira et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma

(2010) Brian O’Nuallain et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Measurement of anti-beta amyloid antibodies in human blood

(2010) Paul Szabo et al.   JOURNAL OF NEUROIMMUNOLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

A RETROSPECTIVE CHART REVIEW OF THE TOLERABILITY AND EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN THE TREATMENT OF ALZHEIMER'S DISEASE

(2008) Gayatri Devi et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING